Viewing Study NCT02364362



Ignite Creation Date: 2024-05-06 @ 3:45 AM
Last Modification Date: 2024-10-26 @ 11:38 AM
Study NCT ID: NCT02364362
Status: COMPLETED
Last Update Posted: 2019-01-18
First Post: 2015-01-19

Brief Title: A Study of Famitinib Plus Docetaxel in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer NSCLC
Sponsor: Jiangsu HengRui Medicine Co Ltd
Organization: Jiangsu HengRui Medicine Co Ltd

Study Overview

Official Title: Docetaxel Plus Famitinib Versus Docetaxel Plus Placebo in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer NSCLC
Status: COMPLETED
Status Verified Date: 2018-12
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Famitinib is a tyrosin-inhibitor agent targeting at c-Kit VEGFR2 PDGFR VEGFR3 Flt1 and Flt3 Phase I study has shown that the toxicity is manageable

This study assessed the safety and maximum tolerated dose of continuous daily treatment with Famitinib plus docetaxel 60 mgm2 every 3 weeks in patients with Advanced Non-squamous and Non-Small Cell Lung Cancer NSCLC to determine the recommended dose for the Phase II trial
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None